Market Exclusive

Analyst Activity – J P Morgan Chase & Co Reiterates Overweight on Clovis Oncology (NASDAQ:CLVS)

Analyst Ratings For Clovis Oncology (NASDAQ:CLVS)

Today, J P Morgan Chase & Co reiterated its Overweight rating on Clovis Oncology (NASDAQ:CLVS).

There are 6 hold ratings, 10 buy ratings on the stock.

The current consensus rating on Clovis Oncology (NASDAQ:CLVS) is Buy (Score: 2.63) with a consensus target price of $79.50 per share, a potential 6.26% downside.

Some recent analyst ratings include

Recent Insider Trading Activity For Clovis Oncology (NASDAQ:CLVS)
Clovis Oncology (NASDAQ:CLVS) has insider ownership of 17.40% and institutional ownership of 90.01%.

Recent Trading Activity for Clovis Oncology (NASDAQ:CLVS)
Shares of Clovis Oncology closed the previous trading session at 81.01 down -3.80 -4.48% with 4,760,938 shares trading hands.

Exit mobile version